Pfizer Says Its COVID-19 Vaccine Appears More Than 90% Effective in Kids
Kid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group. The shots could begin in early November — with the first children in line fully protected by Christmas — if regulators give the go-ahead. Details of Pfizer’s study were posted online. The Food and Drug Administration was expected to post its independent review of the company’s safety and effectiveness data later in the day. Advisers to the FDA will publicly debate the evidence next week. If the agency ultimately authorizes the shots, the Centers for Disease Control and Prevention will make the final decision on who should receive them. [time-brightcove not-tgx=”true”] Full-strength Pfizer shots already are authorized for anyone 12 or older, but pediatricians and many parents are anxiously awaiting protection for younger children to stem rising infections from the extra-contagious delta variant and help keep kids in school. More than 25,000 pediatricians and primary care providers already have signed up to get the shots into little arms. The Biden administration has purchased enough kid-size doses — in special orange-capped vials to distinguish them from adult vaccine — for the nation’s roughly 28 million 5- to 11-year-olds. If the vaccine is cleared, millions of doses will be...
AbstractMore than 12 months have passed since the World Health Organization (WHO) declared Coronavirus Disease 19 (COVID-19), caused by the SARS-CoV2 virus, to be a pandemic on 11 March 2020. The entire world scientific community agrees that at this time vaccine is the most promising weapon to combat the infection and the severity of the disease. According to the document “Draft landscape of COVID-19 candidate vaccines” by WHO, 272 vaccines against SARS-CoV-2 virus are in development, although only four of these, produced by Pfizer-BioNTech (Pfizer, Inc. and BioNTech), Moderna, AstraZeneca, and Janssen companie...
New variant identified in the midst of surging coronavirus cases and vaccination rates that are falling short of the government's target.
A report by the UK Health Security Agency (UKHSA) today revealed just 10,486 (22 per cent of women) who gave birth in August had been given a first dose of the coronavirus vaccine.
Many households with immunocompromised or vulnerable relatives are racing to get Covid shots for their 5-to-11-year-olds — and finally experiencing a long-awaited sense of relief.
The Biden administration has called on major companies to help fight the pandemic. Big chains want to get past the holiday staffing crunch first.
It is the first time the regulator has authorized a Covid-19 vaccine for use in young children.
Documents relating to the new coronavirus (COVID-19) vaccination programme. 25 November 2021Added COVID-19 vaccination in pregnancy surveillance. 15 November 2021Updated'Programme documents'section.
The European Union's drug regulator on Thursday recommended approval of Pfizer's coronavirus vaccine for use on children from five to 11 years old, clearing a path for shots to be administered to millions of elementary school pupils amid a new wave of infections sweeping across the continent.
The European Union drug regulator has authorized Pfizer’s coronavirus vaccine for use on children from 5 to 11 years old
Conclusion: The intensity of the specific immune response in a new coronavirus infection was assessed by the level of Anti SARS-CoV-2 IgG in the blood serum in the dynamics up to 150 days after the manifestation of the disease. It is shown that it is possible to predict the time of complete disappearance of protective specific Anti SARS-COV-2 IgG in the blood serum in the medium term.